Lundbeck and Otsuka win new approval for key product
Denmark’s Lundbeck and its Japan-based partner Otsuka Pharma has gained a new regulatory approval for a key drug to treat schizophrenia.
BY LONNI LYNGE
Lundbeck has won a new regulatory approval for one among a handful of key products from the Danish drug group, as Health Canada has green-lighted the group’s schizophrenia drug Rexulti (brexpiprazole), which is co-developed with Japan’s Otsuka Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck hope wins expanded approval
For abonnenter
JP Morgan calls for increased M&A activity in Lundbeck
For abonnenter
